Research Foundation Of The City University Of New York

Research Foundation Of The City University Of New York, doing business as Rfcuny - Graduate School Of Public Health And Health Policy, operates as a prime recipient and sub-recipient on federal research grants, delivering epidemiological research, public health intervention design and evaluation, and data analysis services to the National Institutes of Health and allied agencies. The entity is a non-profit, tax-exempt organization and a child of The City University Of New York, headquartered at 55 W 125th St Fl 7, New York, NY 10027, competing predominantly in full-and-open federal grant programs rather than set-aside categories.

RFCUNY's grant footprint centers on HIV prevention, mental health services research, epidemiological cohort studies, and public health surveillance and systems innovation, grounded in NIH funding across multiple institutes. The National Institute on Drug Abuse (15 awards), National Institute of Mental Health (14 awards), and National Institute of Allergy and Infectious Diseases (12 awards) collectively account for 54% of recent awards by count. Recent prime grants include a $644,212 NIDA project grant (CFDA 93.279) awarded June 15, 2026 to conduct a randomized controlled trial of INSTAGRAN, a telehealth and urine tenofovir self-testing intervention to enhance pre-exposure prophylaxis adherence among men who have sex with men who use methamphetamine, extending through March 31, 2031; a $2.3 million NIAID cooperative agreement (CFDA 93.855) awarded June 4, 2026 for Proyecto Vida, a three-year longitudinal epidemiological study of HIV incidence and prevention engagement among Colombian men who have sex with men, concluding May 31, 2028; and a $1.057 million NIMH project grant (CFDA 93.242) awarded September 19, 2025 to implement and evaluate the STREAMS intervention combining streamlined interpersonal psychotherapy groups and family-based medication adherence counseling for adolescents living with HIV in Uganda, extending through May 31, 2030. RFCUNY also holds smaller prime contracts with the Centers for Disease Control and Prevention (youth digital marketing surveillance surveillance) and the National Institutes of Health institutes (simulation modeling in health disparities research, clinical study simulation models, scientific consulting and analysis) valued at $561 thousand to $75 thousand. The entity acts as a sub-recipient on grant awards from major prime recipients including New York University, Columbia University, Yale University, Vanderbilt University Medical Center, and Icahn School of Medicine at Mount Sinai, performing epidemiological and statistical analysis, qualitative research, implementation science, and systems modeling work on HIV cohort research, cardiovascular disease studies, cancer genomics infrastructure, vaccine hesitancy and COVID-19 vaccination research, and community mental health system transformation initiatives.

Activity has grown substantially, from 9 awards in 2022 to 21 in 2024, though the combined potential value of $699 thousand across 107 total awards (57 prime, 50 sub) reflects the grant-funded research posture — NIH project and cooperative agreements typically carry modest five-year budgets relative to federal contract vehicles. Twelve awards with ultimate completion dates in the next twenty-four months face recompete exposure carrying $75 thousand in combined potential value. RFCUNY's capability portfolio is distinctly epidemiological and behavioral: longitudinal cohort study design and management, HIV prevention and treatment adherence research, systems science and implementation science applied to public health, qualitative and mixed-methods research on social and structural determinants of health, and data curation and biostatistical analysis. The Graduate School of Public Health and Health Policy itself serves as the institutional home for faculty leadership across these research domains, with named faculty including Denis Nash (epidemiology and implementation science), Luisa Borrell (social epidemiology), Levi Waldron (biostatistics and cancer genomics), and Terry Huang (systems science and community health), reflecting deep specialization in NIH-funded research rather than commercial contract delivery.